

Bone Morphogenetic Proteins Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 200 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4999.00
- Five User License \$5999.00
- Corporate License \$6999.00

Report description:

Global Bone Morphogenetic Proteins Market Report and Forecast 2024-2032?

The global bone morphogenetic proteins (BMP) market is expected to grow at a CAGR of 2.3% during the period 2024-2032. This growth is driven by advancements in BMP technologies, increasing demand for orthopaedic and reconstructive surgeries, and the rising prevalence of bone-related disorders, alongside supportive government policies and healthcare investments.

Global Bone Morphogenetic Proteins Market Analysis

The global bone morphogenetic proteins (BMP) market is experiencing substantial growth due to advancements in medical technologies and increasing applications in orthopaedic and reconstructive surgeries. BMPs are critical for promoting bone growth and healing, making them essential in various medical procedures aimed at bone regeneration and repair. Their expanding use in spinal fusion, trauma, reconstructive, and oral-maxillofacial surgeries underscores their importance in modern medical treatments, driving significant market growth.

Market Driver

- ☐ **Technological Advancements:** Continuous innovation in BMP technology has significantly enhanced the effectiveness and safety of these proteins in medical applications. These advancements are driving market growth as healthcare providers seek more reliable and efficient solutions for bone regeneration. Improved delivery systems and formulations are making BMPs more effective and appealing for clinical use. Additionally, advancements in biotechnology are enabling the development of recombinant BMPs with enhanced therapeutic properties, further broadening their application in orthopaedic and reconstructive surgeries.

- ☐ **Increasing Prevalence of Bone Disorders:** The rising incidence of bone-related disorders, such as osteoporosis, fractures, and spinal issues, is driving the demand for BMPs. These proteins are crucial in promoting bone healing and regeneration, making them essential in the treatment of various bone disorders. The growing elderly population, which is more prone to bone-related ailments, is also contributing to increased demand for BMP-based therapies, supporting market expansion.

- ☐ **Growing Demand for Orthopaedic Surgeries:** The increasing number of orthopaedic surgeries, including spinal fusion and trauma surgeries, is boosting the demand for BMPs. These proteins play a vital role in enhancing the success rate of these surgeries by promoting bone growth and fusion. The trend towards minimally invasive surgical techniques, which often utilise BMPs, is further

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

driving their adoption in orthopaedic procedures, enhancing patient outcomes and recovery times.

-□Supportive Government Policies: Government initiatives and funding are promoting research and development in the field of BMPs. Supportive policies and financial incentives for innovation in medical technologies are contributing to market growth, making advanced BMP therapies more accessible. Government support is also facilitating the faster approval and adoption of BMP-based products, encouraging pharmaceutical companies to invest in BMP research and development.

Market Challenges

-□High Costs: The high cost of BMP therapies can limit accessibility, especially in low-income regions. This financial barrier is a significant challenge to the widespread adoption of BMP technologies. The costs include not only the BMP products themselves but also the associated surgical procedures and post-operative care. Efforts to reduce costs and improve affordability are essential to expanding market reach and ensuring that more patients can benefit from these advanced therapies.

-□Regulatory Hurdles: Stringent regulatory requirements for the approval and certification of BMP products can delay market entry and increase development costs. These regulatory challenges can be significant obstacles for manufacturers aiming to introduce new BMP technologies. Navigating complex regulatory landscapes and ensuring compliance with varying international standards are critical to bringing innovative BMP therapies to market efficiently.

-□Potential Side Effects: The potential side effects and complications associated with BMP therapies, such as inflammation and unwanted bone growth, pose challenges to their use. Ensuring patient safety and addressing these concerns through research and improved formulations are crucial for market growth. Continuous monitoring and post-market surveillance are necessary to mitigate these risks and maintain the trust of healthcare providers and patients.

-□Limited Awareness: The limited awareness and understanding of BMP therapies among patients and some healthcare providers can hinder market growth. Educational initiatives and awareness campaigns are necessary to promote the benefits and applications of BMPs. Increasing knowledge about the effectiveness and safety of BMP therapies can encourage wider adoption and integration into standard medical practices.

Future Opportunities

-□Emerging Markets: Expanding into emerging markets with improving healthcare infrastructure presents substantial growth opportunities. These regions offer untapped potential for increasing access to BMP therapies and improving patient outcomes. Strategic investments and partnerships in these areas can drive market growth and enhance the availability of reliable BMP technologies.

-□Development of Novel BMP Therapies: The development of novel BMP therapies and delivery systems can enhance the effectiveness and safety of these treatments. Innovations in BMP formulations and applications are expected to drive market growth by providing more targeted and efficient solutions. New delivery methods, such as sustained-release formulations, can improve patient compliance and therapeutic outcomes.

-□Collaborations and Partnerships: Strategic partnerships between biotechnology companies, research institutions, and healthcare providers can drive market expansion. Collaborations can facilitate research, development, and distribution efforts, enhancing the availability and quality of BMP therapies. Joint ventures and alliances are essential for leveraging expertise and resources to innovate and expand market offerings.

-□Increasing Applications in Dental and Maxillofacial Surgeries: The growing use of BMPs in dental and maxillofacial surgeries presents new opportunities for market growth. BMPs are increasingly being used to promote bone regeneration in these areas, expanding their application scope. Enhanced techniques and better outcomes in these fields can drive further adoption and development of BMP-based products.

Market Trends

-□Rising Adoption in Spinal Fusion Surgeries: The adoption of BMPs in spinal fusion surgeries is increasing due to their effectiveness in promoting bone growth and fusion. This trend is driving market growth as more orthopaedic surgeons incorporate BMPs into

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

their surgical procedures. The positive outcomes associated with BMP use in spinal fusion are encouraging wider adoption across orthopaedic practices.

- Focus on Minimally Invasive Procedures: There is a growing trend towards minimally invasive surgical procedures, which often utilise BMPs for bone regeneration. This focus on less invasive techniques is enhancing patient recovery times and overall surgical outcomes, supporting market growth. Minimally invasive approaches that incorporate BMPs are becoming more popular due to their reduced risk and faster recovery compared to traditional methods.

- Increased Investment in R&D: Investment in research and development for BMP technologies is on the rise. Companies are dedicating significant resources to discovering new BMP applications and improving existing therapies, fostering innovation in the market. Enhanced R&D efforts are expected to yield advanced BMP solutions that offer better efficacy and safety profiles.

- Emphasis on Patient Safety and Efficacy: Ensuring the safety and efficacy of BMP therapies is a top priority. Advances in BMP formulations and delivery systems are enhancing the reliability of these treatments, supporting market growth. The emphasis on patient safety is expected to continue driving innovation and adoption in the BMP market, ensuring that new products meet stringent safety standards.

Global Bone Morphogenetic Proteins Market Segmentation

Market Breakup by Type

- Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2

- Recombinant Human Bone Morphogenetic Protein (rhBMP) - 7

The global bone morphogenetic proteins (BMP) market is segmented by type into recombinant human bone morphogenetic protein (rhBMP) - 2 and recombinant human bone morphogenetic protein (rhBMP) - 7. Both types are crucial in promoting bone growth and healing, with rhBMP-2 being widely used in spinal fusion and trauma surgeries, while rhBMP-7 is often utilised in reconstructive and maxillofacial surgeries. These segments drive market growth by providing effective solutions for various bone-related conditions, supported by continuous advancements in BMP technology.

Market Breakup by Application

- Spinal Fusion

- Trauma

- Reconstructive Surgery

- Oral-maxillofacial

The market is segmented by application into spinal fusion, trauma, reconstructive surgery, and oral-maxillofacial. Spinal fusion applications dominate due to the high success rate of BMPs in promoting bone fusion and reducing recovery times. Trauma and reconstructive surgeries also benefit significantly from BMPs, which enhance bone regeneration and healing. The growing use of BMPs in oral-maxillofacial surgeries highlights their expanding application scope, contributing to overall market growth.

Market Breakup by Region

- North America?

- Europe

- Asia Pacific

- Latin America

- Middle East and Africa

The global bone morphogenetic proteins (BMP) market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe lead the market due to advanced healthcare infrastructure and high adoption of BMP technologies. The Asia Pacific region is emerging as a significant growth area, driven by improving healthcare access and increasing demand for orthopaedic and reconstructive surgeries. Latin America the Middle East and Africa are also poised for growth, supported by rising healthcare investments and awareness initiatives.

Global Bone Morphogenetic Proteins Market Competitive Landscape

The global bone morphogenetic proteins (BMP) market features several key players actively shaping the competitive landscape. Notable companies include Thermo Fisher Scientific, Inc., Medtronic Plc, Prospec-Tany Technogene Ltd., Merck KGaA, Stryker Corporation, Cellumed Co. Ltd, Ember Therapeutics Inc., Nuvasive Inc, Orthofix Holdings, Inc., and Smith and Nephew Inc. These

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

companies engage in activities such as mergers and acquisitions, research initiatives, product introductions, and strategic partnerships to expand their market presence and capabilities. These activities drive innovation and growth within the BMP market, ensuring continuous improvement and broadening service offerings.

Key Questions Answered in the Report

- How are technological advancements enhancing the effectiveness and safety of BMP therapies?
- What role do government policies and funding play in promoting the BMP market?
- How does the increasing prevalence of bone-related disorders impact the demand for BMPs?
- In what ways are advancements in orthopaedic and reconstructive surgeries driving the BMP market?
- What challenges are associated with the high costs of BMP therapies?
- How do regulatory hurdles affect the introduction of new BMP technologies?
- What are the potential side effects and complications associated with BMP therapies?
- How can emerging markets provide growth opportunities for the BMP market?
- What innovations are being developed in BMP formulations and delivery systems?
- How are strategic partnerships influencing research and development in the BMP market?
- What trends are shaping the future of the BMP market, including the adoption of minimally invasive procedures and increased investment in R&D?

Key Benefits for Stakeholders

- The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global bone morphogenetic proteins (BMP) market from 2017-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the global bone morphogenetic proteins (BMP) market.
- The study maps the leading, as well as the fastest-growing, regional markets, enabling stakeholders to identify key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the global bone morphogenetic proteins (BMP) industry and its attractiveness.
- The competitive landscape section allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Table of Contents:

- 1□Preface
- 1.1□Objectives of the Study
- 1.2□Key Assumptions
- 1.3□Report Coverage - Key Segmentation and Scope
- 1.4□Research Methodology
- 2□Executive Summary
- 3□Global Bone Morphogenetic Proteins Market Overview
- 3.1□Global Bone Morphogenetic Proteins Market Historical Value (2017-2023)
- 3.2□Global Bone Morphogenetic Proteins Market Forecast Value (2024-2032)
- 4□Vendor Positioning Analysis
- 4.1□Key Vendors

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.2□Prospective Leaders
- 4.3□Niche Leaders
- 4.4□Disruptors
- 5□Global Bone Morphogenetic Proteins Market Landscape*
- 5.1□Global Bone Morphogenetic Proteins: Developers Landscape
- 5.1.1□Analysis by Year of Establishment
- 5.1.2□Analysis by Company Size
- 5.1.3□Analysis by Region
- 5.2□Global Bone Morphogenetic Proteins: Product Landscape
- 5.2.1□Analysis by Type
- 5.2.2□Analysis by Application
- 6□Global Bone Morphogenetic Proteins Market Dynamics
- 6.1□Market Drivers and Constraints
- 6.2□SWOT Analysis
- 6.2.1□Strengths
- 6.2.2□Weaknesses
- 6.2.3□Opportunities
- 6.2.4□Threats
- 6.3□PESTEL Analysis
- 6.3.1□Political
- 6.3.2□Economic
- 6.3.3□Social
- 6.3.4□Technological
- 6.3.5□Legal
- 6.3.6□Environment
- 6.4□Porter's Five Forces Model
- 6.4.1□Bargaining Power of Suppliers
- 6.4.2□Bargaining Power of Buyers
- 6.4.3□Threat of New Entrants
- 6.4.4□Threat of Substitutes
- 6.4.5□Degree of Rivalry
- 6.5□Key Demand Indicators
- 6.6□Key Price Indicators
- 6.7□Industry Events, Initiatives, and Trends
- 6.8□Value Chain Analysis
- 7□Global Bone Morphogenetic Proteins Market Segmentation (2017-2032)
- 7.1□Global Bone Morphogenetic Proteins Market (2017-2032) by Type
- 7.1.1□Market Overview
- 7.1.2□Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2
- 7.1.3□Recombinant Human Bone Morphogenetic Protein (rhBMP) -7
- 7.2□Global Bone Morphogenetic Proteins Market (2017-2032) by Application
- 7.2.1□Market Overview
- 7.2.2□Spinal Fusion
- 7.2.3□Trauma
- 7.2.4□Reconstructive Surgery
- 7.2.5□Oral-maxillofacial
- 7.3□Global Bone Morphogenetic Proteins Market (2017-2032) by Region

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.1□Market Overview
- 7.3.2□North America
- 7.3.3□Europe
- 7.3.4□Asia Pacific
- 7.3.5□Latin America
- 7.3.6□Middle East and Africa
- 8□North America Bone Morphogenetic Proteins Market (2017-2032)
- 8.1□North America Bone Morphogenetic Proteins Market (2017-2032) by Type
- 8.1.1□Market Overview
- 8.1.2□Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2
- 8.1.3□Recombinant Human Bone Morphogenetic Protein (rhBMP) -7
- 8.2□North America Bone Morphogenetic Proteins Market (2017-2032) by Application
- 8.2.1□Market Overview
- 8.2.2□Spinal Fusion
- 8.2.3□Trauma
- 8.2.4□Reconstructive Surgery
- 8.2.5□Oral-maxillofacial
- 8.3□North America Bone Morphogenetic Proteins Market (2017-2032) by Country
- 8.3.1□United States of America
- 8.3.2□Canada
- 9□Europe Bone Morphogenetic Proteins Market (2017-2032)
- 9.1□Europe Bone Morphogenetic Proteins Market (2017-2032) by Type
- 9.1.1□Market Overview
- 9.1.2□Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2
- 9.1.3□Recombinant Human Bone Morphogenetic Protein (rhBMP) -7
- 9.2□Europe Bone Morphogenetic Proteins Market (2017-2032) by Application
- 9.2.1□Market Overview
- 9.2.2□Spinal Fusion
- 9.2.3□Trauma
- 9.2.4□Reconstructive Surgery
- 9.2.5□Oral-maxillofacial
- 9.3□Europe Bone Morphogenetic Proteins Market (2017-2032) by Country
- 9.3.1□United Kingdom
- 9.3.2□Germany
- 9.3.3□France
- 9.3.4□Italy
- 9.3.5□Others
- 10□Asia Pacific Bone Morphogenetic Proteins Market (2017-2032)
- 10.1□Asia Pacific Bone Morphogenetic Proteins Market (2017-2032) by Type
- 10.1.1□Market Overview
- 10.1.2□Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2
- 10.1.3□Recombinant Human Bone Morphogenetic Protein (rhBMP) -7
- 10.2□Asia Pacific Bone Morphogenetic Proteins Market (2017-2032) by Application
- 10.2.1□Market Overview
- 10.2.2□Spinal Fusion
- 10.2.3□Trauma
- 10.2.4□Reconstructive Surgery

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.2.5□Oral-maxillofacial
- 10.3□Asia Pacific Bone Morphogenetic Proteins Market (2017-2032) by Country
 - 10.3.1□China
 - 10.3.2□Japan
 - 10.3.3□India
 - 10.3.4□ASEAN
 - 10.3.5□Australia
 - 10.3.6□Others
- 11□Latin America Bone Morphogenetic Proteins Market (2017-2032)
 - 11.1□Latin America Bone Morphogenetic Proteins Market (2017-2032) by Type
 - 11.1.1□Market Overview
 - 11.1.2□Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2
 - 11.1.3□Recombinant Human Bone Morphogenetic Protein (rhBMP) -7
 - 11.2□Latin America Bone Morphogenetic Proteins Market (2017-2032) by Application
 - 11.2.1□Market Overview
 - 11.2.2□Spinal Fusion
 - 11.2.3□Trauma
 - 11.2.4□Reconstructive Surgery
 - 11.2.5□Oral-maxillofacial
 - 11.3□Latin America Bone Morphogenetic Proteins Market (2017-2032) by Country
 - 11.3.1□Brazil
 - 11.3.2□Argentina
 - 11.3.3□Mexico
 - 11.3.4□Others
- 12□Middle East and Africa Bone Morphogenetic Proteins Market (2017-2032)
 - 12.1□Middle East and Africa Bone Morphogenetic Proteins Market (2017-2032) by Type
 - 12.1.1□Market Overview
 - 12.1.2□Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2
 - 12.1.3□Recombinant Human Bone Morphogenetic Protein (rhBMP) -7
 - 12.2□Middle East and Africa Bone Morphogenetic Proteins Market (2017-2032) by Application
 - 12.2.1□Market Overview
 - 12.2.2□Spinal Fusion
 - 12.2.3□Trauma
 - 12.2.4□Reconstructive Surgery
 - 12.2.5□Oral-maxillofacial
 - 12.3□Middle East and Africa Bone Morphogenetic Proteins Market (2017-2032) by Country
 - 12.3.1□Saudi Arabia
 - 12.3.2□United Arab Emirates
 - 12.3.3□Nigeria
 - 12.3.4□South Africa
 - 12.3.5□Others
- 13□Regulatory Framework
 - 13.1□Regulatory Overview
 - 13.2□US FDA
 - 13.3□EU EMA
 - 13.4□INDIA CDSCO
 - 13.5□JAPAN PMDA

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.6□Others
- 14□Patent Analysis
 - 14.1□ Analysis by Type of Patent
 - 14.2□ Analysis by Publication Year
 - 14.3□ Analysis by Issuing Authority
 - 14.4□ Analysis by Patent Age
 - 14.5□ Analysis by CPC Analysis
 - 14.6□ Analysis by Patent Valuation
 - 14.7□ Analysis by Key Players
- 15□Clinical Trial Analysis
 - 15.1□Analysis by Trial Registration Year
 - 15.2□Analysis by Trial Status
 - 15.3□Analysis by Trial Phase
 - 15.4□Analysis by Therapeutic Area
 - 15.5□Analysis by Geography
- 16□Funding and Investment Analysis
 - 16.1□ Analysis by Funding Instances
 - 16.2□ Analysis by Type of Funding
 - 16.3□ Analysis by Funding Amount
 - 16.4□ Analysis by Leading Players
 - 16.5□ Analysis by Leading Investors
 - 16.6□ Analysis by Geography
- 17□Strategic Initiatives
 - 17.1□ Analysis by Partnership Instances
 - 17.2□ Analysis by Type of Partnership
 - 17.3□ Analysis by Leading Players
 - 17.4□ Analysis by Geography
- 18□Supplier Landscape
 - 18.1□Market Share Analysis, By Region (Top 5 Companies)
 - 18.1.1□Market Share Analysis: Global
 - 18.1.2□Market Share Analysis: North America
 - 18.1.3□Market Share Analysis: Europe
 - 18.1.4□Market Share Analysis: Asia Pacific
 - 18.1.5□Market Share Analysis: Others
 - 18.2□ Thermo Fisher Scientific, Inc .
 - 18.2.1□Financial Analysis
 - 18.2.2□Product Portfolio
 - 18.2.3□Demographic Reach and Achievements
 - 18.2.4□Mergers and Acquisitions
 - 18.2.5□Certifications
 - 18.3□Medtronic Plc
 - 18.3.1□Financial Analysis
 - 18.3.2□Product Portfolio
 - 18.3.3□Demographic Reach and Achievements
 - 18.3.4□Mergers and Acquisitions
 - 18.3.5□Certifications
 - 18.4□Prospec-Tany Technogene Ltd .

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Merck KGaA .
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Stryker Corporation
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Cellumed Co. Ltd
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Ember Therapeutics Inc .
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Nuvasive Inc
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Orthofix Holdings, Inc .
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Smith and Nephew Inc .
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

19□Global Bone Morphogenetic Proteins Market - Distribution Model (Additional Insight)

19.1□ Overview

19.2□ Potential Distributors

19.3□ Key Parameters for Distribution Partner Assessment

20□Key Opinion Leaders (KOL) Insights (Additional Insight)

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Bone Morphogenetic Proteins Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 200 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4999.00
	Five User License	\$5999.00
	Corporate License	\$6999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-06"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com